IGY Life Sciences gets listed on THE OCMX™

The OCMX™ is pleased to announce the listing of IGY Life Sciences to its online portal which offers Investors and Advisors the ability to learn more about this exciting opportunity.

THUNDER BAY, ON, October 25, 2021 /24-7PressRelease/ -- IGY Immune Technologies & Life Sciences Inc. is focused on development and manufacturing of Immunoglobulin Y (IgY) antibodies, which are harvested from chicken eggs. IGY Antibodies are highly concentrated in egg yolk and our unique technology makes it possible to extract large quantities of highly purified antibodies from chicken eggs. At 1/100 the cost of monoclonal antibodies, IgY is a game changer for the pharmaceutical industry.

We develop specific types of naturally occurring antibodies, designed to address many health concerns such as COVID-19, influenza, African Swine Fever, H. pylori and celiac disease.

We hold related intellectual property rights and patents. We are capable of producing these antibodies in a large-scale production capacity and getting into market quickly.

The OCMX™ is pleased to announce the listing of IGY Life Sciences to its online portal which offers Investors and Advisors the ability to learn more about this exciting opportunity.

The OCMX™ has spent considerable time completing its due diligence on IGY Life Sciences and concluded that there is indeed a tremendous potential for this opportunity.

The OCMX™ noted that IGY Life Sciences exhibits the main components of any solid opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.

SOLUTION PROVIDED BY COMPANY
We have IgY-110,
• Antibody to address COVID-19 as a therapeutic and prophylactic that is simple and effective
• Can be part of a treatment or prevention strategy,
• Comes from a natural source,
• Is stable in the gut and will not create inflammation, and
• Address anti-vaccine population.
• Propriety biotechnology platform that allows for the extraction of IgY antibodies from the eggs of immunized chickens and IgY for the immune market,
• Ease of distribution for therapeutic and prophylactic products that can be transported and stored without any special requirements (like refrigeration).

WHERE THEY ARE HEADED
Our mission is to actualize the promise of IgY technology to enable humans and animals to live healthy lives.

Development and production of a COVID-19 therapeutic and prophylactic antibody in a nasal spray/drop form, while at the same time, developing and producing nutraceutical and African Swine Fever IgY products.

Will manufacture antibodies in a new production facility located in Airdrie Alberta.

MANAGEMENT TEAM
Terry Dyck, President & CEO
Founder and serial entrepreneur, comes with over fifteen years of growing sales and building business. Purchased the IgY extraction technology in 2009. Has lead the team to new heights in terms of product development, improvements to the extraction technology and new I.P.

Huan Nguyen, PhD, Chief Scientific Officer
Dr Huan was previously a Lead Researcher at the International Vaccine Institute, where he created IgY applications in Avian Influenza, Human Influenza and Rotavirus. Since joining IGY Life Sciences, he continues to add to his portfolio with applications in IBD, H. Pylori and most recently, ASF.

Sandra Leonetti, Chief Financial Officer
Sandra Leonetti is a Fellow Chartered Professional Accountant (FCPA) with more than 20 years of experience as a senior level finance professional in both privately held and listed organizations. Her career spans over several decades of experience in financial management and reporting, business leadership and corporate strategy.

David Mason, Chief of Production
David is a joint inventor of the IgY extraction technology, and a world leader is protein extraction from eggs. Holds a number of key patents in this field. David spent 17 years in the brokerage industry, where he obtained experience in finance, corporate underwritings, management and sales.

ABOUT THE OCMX™

The OCMX™ is changing how companies generate exposure in the financial marketplace and raise funds as we know it. The OCMX™ serves both public and private companies in need of market exposure during financial raises. It does this by way of connecting the relevant companies with financial institutions all in one online transparent portal. The OCMX™ (P2P Financial Inc.) launched in September of 2009 out of Toronto but has since expanded its operations to include Quebec, Alberta, Manitoba, and British Columbia.

The OCMX™ connects investors and advisors directly with companies seeking to raise funds or gain broad market exposure. The OCMX™ provides an open venue for innovative growth companies and leading investment funds to generate market awareness, raise funds, or connect with investors and advisors.

The OCMX™ provides companies, funds, investors, and advisors instant access to its Online Portal so that they can actively source and connect with their next opportunity, advisor, investor, client, or financing partner.

Contact Us
The OCMX™
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
Tel: 1-866-209-6862
Email: prosper@theocmx.com

IGY Life Sciences gets listed on THE OCMX™
https://theocmx.com/marketplace/igy-life-sciences/



---
Press release service and press release distribution provided by http://www.24-7pressrelease.com